Novo Nordisk’s senior vice president of US operations Dave Moore discusses the producer’s newly launched once-a-day oral weight loss pill on ‘The Claman Countdown.’
Wegovy’s oral version of its injectable weight-loss drug is seeing a lot of interest, Novo Nordisk CEO Dave Moore told FOX Business on Friday.
Wegovy’s once-daily pill, an oral weight loss pill, was approved in December 2025 by the Food and Drug Administration as the first oral GLP-1 drug and was launched on the US market on Monday.
“There are a lot of patients who have been sitting on the sidelines waiting because they didn’t really see themselves being treated with an injection,” Moore, Novo Nordisk’s senior vice president of US Operations, told “The Claman Countdown.” “Now that the pill is available, we’re seeing a lot of interest and a lot of activity.”
DRUGS ADD YEARS TO AMERICAN’S LIVES, RESEARCHERS PROJECT
Wegovy injection pens are planned in Waterbury, Vermont, on April 28, 2025. (Shelby Knowles/Bloomberg via Getty Images/Getty Images)
Drug maker Novo Nordisk makes Wegovy. Moore told FOX Business that clinical trials show the pill delivers the same weight loss results as an injection.
“There is not much difference,” explained the drug official. “That’s what we’re very happy about. That’s what we’re proud of at Novo Nordisk is that patients now don’t have to choose. They don’t have to compromise.”
The pill will be available at 70,000 pharmacies nationwide, including supermarkets such as CVS, Costco and Good Rx.
PICK UP PROTEINS, DONATIONS, JOIN THE COMPANY ON AWESOME ISSUES
Wegovy is modeled as an injectable weight loss drug. (Michael Siluk/UCG/Universal Images Group via Getty Images/Getty Images)
The price of the semaglutide pill is lower than that of the injectable version for those who pay cash. Eligible, insured customers will pay about $25 a month while the uninsured will pay $149 a month, FOX Business anchor Liz Claman reported.
Moore noted that the cost of the pill and the injection are about the same as Novo Nordisk’s, but making the pill affordable was a priority for the drugmaker.
In addition to the low price, he also highlighted the secondary benefits associated with Wegovy in addition to weight loss.
“Both the injection and the pill have secondary indications, and that is to reduce the risk of heart disease,” Moore said.
The FDA classifies the drug as a drug to prevent heart disease.
AMERICA’S COMMUNICATION CRISIS MEETS OZEMPIC BOOM AS DATA SHOWS GLP-1 HOTSPOTS
While Wegovy’s pill is the only FDA-approved oral GLP-1 weight loss drug, Novo Nordisk’s competitor Eli Lilly is reportedly close to getting its own oral version approved.
Eli Lilly headquarters in Indianapolis, Indiana, on May 3, 2023. (AJ Mast/Bloomberg via Getty Images/Getty Images)
Moore also addressed concerns about what happens when patients stop taking GLP-1 drugs, noting that many regain weight.
“If you stop the treatment, it is possible that the weight comes back, and it is important that the treatment is long,” he said.
“If you’re taking medication for hypertension or diabetes, long-term treatment is necessary,” added Moore.
GET FOX BUSINESS ON THE GO BY CLICKING HERE
Claman asked if Novo Nordisk is exploring alternatives that don’t require lifelong use.
“There’s a lot of R&D [research and development] that’s happening, and of course, we’re in the middle of that,” Moore said.
